|
CA2720682A1
(en)
*
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
EP3974453A3
(en)
*
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
KR101972446B1
(ko)
*
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
TWI679212B
(zh)
*
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
RU2766608C2
(ru)
*
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
|
WO2014068079A1
(en)
|
2012-11-01 |
2014-05-08 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
WO2014124280A1
(en)
|
2013-02-08 |
2014-08-14 |
Institute For Myeloma & Bone Cancer Research |
Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
|
|
AR095374A1
(es)
*
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
BR112016018100A2
(pt)
|
2014-02-07 |
2018-02-20 |
Univ Mcmaster |
acoplador antigênico de células t trifuncional, métodos e usos do mesmo
|
|
JP6825910B2
(ja)
|
2014-03-26 |
2021-02-03 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） |
Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
|
KR102526945B1
(ko)
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
BR112017001183A2
(pt)
*
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
BR112017001385B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
ES2878449T3
(es)
*
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
KR102476226B1
(ko)
|
2014-08-05 |
2022-12-12 |
아폴로믹스 인코포레이티드 |
항-pd-l1 항체
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
TWI703159B
(zh)
*
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
PL3298033T5
(pl)
*
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
WO2017019496A1
(en)
*
|
2015-07-24 |
2017-02-02 |
Berenson James Richard |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
SI3331910T1
(sl)
*
|
2015-08-03 |
2020-07-31 |
Engmab Sarl |
Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
|
|
MX2018002043A
(es)
|
2015-08-17 |
2018-07-06 |
Janssen Pharmaceutica Nv |
ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
|
|
JP2018534264A
(ja)
|
2015-09-28 |
2018-11-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
|
|
CN108473575B
(zh)
*
|
2015-11-13 |
2022-04-19 |
美国卫生和人力服务部 |
抗-bcma多肽和蛋白质
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
ES2898329T3
(es)
|
2016-01-12 |
2022-03-07 |
Oncotracker Inc |
Métodos mejorados para supervisar el estado inmunitario de un sujeto
|
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
IL313507A
(en)
*
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
TWI795133B
(zh)
|
2016-04-01 |
2023-03-01 |
美商凱特製藥公司 |
Ｂｃｍａ結合分子類及彼等之用途
|
|
CA3019650C
(en)
|
2016-04-01 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
PE20241349A1
(es)
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP7267914B2
(ja)
|
2016-11-02 |
2023-05-02 |
エンクマフ エスアーエールエル |
Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
|
|
WO2018085690A1
(en)
|
2016-11-04 |
2018-05-11 |
Bluebird Bio, Inc. |
Anti-bcma car t cell compositions
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
WO2018158349A1
(en)
|
2017-02-28 |
2018-09-07 |
Affimed Gmbh |
Tandem diabody for cd16a-directed nk-cell engagement
|
|
WO2018174274A1
(ja)
|
2017-03-24 |
2018-09-27 |
全薬工業株式会社 |
抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN118948892A
(zh)
|
2017-05-01 |
2024-11-15 |
朱诺治疗学股份有限公司 |
细胞疗法与免疫调节化合物的组合
|
|
US11635435B2
(en)
|
2017-06-13 |
2023-04-25 |
Oncotracker, Inc. |
Diagnostic, prognostic, and monitoring methods for solid tumor cancers
|
|
JP2020523383A
(ja)
|
2017-06-14 |
2020-08-06 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
MA51447A
(fr)
|
2017-08-01 |
2020-06-10 |
Medimmune Llc |
Conjugué anticorps monoclonal-médicament dirigé contre bcma
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
EP3681908A1
(en)
|
2017-09-13 |
2020-07-22 |
Teneobio, Inc. |
Heavy chain antibodies binding to ectoenzymes
|
|
CN111201243B
(zh)
*
|
2017-09-29 |
2023-08-11 |
财团法人牧岩生命科学研究所 |
对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物
|
|
CN111479925B
(zh)
|
2017-10-12 |
2024-03-08 |
麦克马斯特大学 |
具有y182t突变的t细胞-抗原偶联物及其方法和用途
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
MX2020005907A
(es)
|
2017-12-08 |
2020-10-19 |
Juno Therapeutics Inc |
Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
CN111683966B
(zh)
|
2017-12-22 |
2023-07-11 |
特尼奥生物股份有限公司 |
与cd22结合的重链抗体
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3674327A4
(en)
|
2018-02-01 |
2021-05-05 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
BINDING OF CHIMERIC ANTIGEN RECEPTOR (CAR) TO BCMA AND USES THEREOF
|
|
PT3674328T
(pt)
|
2018-02-01 |
2024-03-14 |
Innovent Biologics Suzhou Co Ltd |
Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo
|
|
US11807663B2
(en)
*
|
2018-02-01 |
2023-11-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CA3089230A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
WO2019173417A1
(en)
*
|
2018-03-08 |
2019-09-12 |
Phanes Therapeutics, Inc. |
Anti-tip-1 antibodies and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3095373A1
(en)
|
2018-04-13 |
2019-10-17 |
Affimed Gmbh |
Nk cell engaging antibody fusion constructs
|
|
UA130542C2
(uk)
|
2018-05-16 |
2026-03-18 |
Янссен Байотек, Інк. |
Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
EP3777895A4
(en)
*
|
2018-06-26 |
2021-12-22 |
ABL Bio Inc. |
ANTI-BCMA ANTIBODIES AND ASSOCIATED USE
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
BR112020024074A2
(pt)
|
2018-07-20 |
2021-02-17 |
Teneobio, Inc. |
anticorpos de cadeia pesada com ligação a cd19
|
|
US12516099B2
(en)
|
2018-08-09 |
2026-01-06 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
WO2020034081A1
(en)
*
|
2018-08-14 |
2020-02-20 |
Hrain Biotechnology Co., Ltd. |
Bcma-targeting chimeric antigen receptor and uses thereof
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
KR20210086651A
(ko)
|
2018-10-26 |
2021-07-08 |
테네오바이오, 인코포레이티드 |
Cd38에 결합하는 중쇄 항체
|
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
SMT202400408T1
(it)
|
2019-01-16 |
2024-11-15 |
Caribou Biosciences Inc |
Anticorpo umanizzato bcma e cellule bcma-car-t
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
WO2020224605A1
(zh)
|
2019-05-07 |
2020-11-12 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
US11840575B2
(en)
|
2019-05-07 |
2023-12-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cells targeting BCMA and their uses thereof
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
WO2021022304A2
(en)
|
2019-07-30 |
2021-02-04 |
Qlsf Biotherapeutics, Inc. |
MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
|
|
MX2022001065A
(es)
*
|
2019-07-30 |
2022-02-14 |
Shanghai Hansoh Biomedical Co Ltd |
Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
|
|
CN112409482B
(zh)
*
|
2019-08-20 |
2022-08-26 |
杭州尚健生物技术有限公司 |
Bcma抗体
|
|
EP4032907A4
(en)
*
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
Bcma-targeted antibody and chimeric antigen receptor
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CA3160765A1
(en)
|
2019-12-10 |
2021-06-17 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CN115023441A
(zh)
|
2019-12-18 |
2022-09-06 |
特诺福尔股份有限公司 |
与cd38结合的重链抗体
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021136323A1
(en)
*
|
2020-01-03 |
2021-07-08 |
Salubris (Chengdu) Biotech Co., Ltd. |
Antibodies binding bcma and uses thereof
|
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
KR20220141299A
(ko)
|
2020-01-14 |
2022-10-19 |
신테카인, 인크. |
Il2 오르토로그 및 사용 방법
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞形質導入のための方法
|
|
IL295381B1
(en)
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
|
|
CN113248611B
(zh)
*
|
2020-02-13 |
2026-02-06 |
上海泰槿生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
JP2023522857A
(ja)
|
2020-04-10 |
2023-06-01 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
|
|
US20230165872A1
(en)
|
2020-04-28 |
2023-06-01 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
TW202330622A
(zh)
|
2020-04-29 |
2023-08-01 |
美商泰尼歐生物公司 |
具有經修飾重鏈恆定區之多特異性重鏈抗體
|
|
JP2023524875A
(ja)
|
2020-05-11 |
2023-06-13 |
ヤンセン バイオテツク，インコーポレーテツド |
多発性骨髄腫を治療するための方法
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
CN116472049A
(zh)
|
2020-06-30 |
2023-07-21 |
特尼奥生物股份有限公司 |
与bcma结合的多特异性抗体
|
|
US20230203178A1
(en)
*
|
2020-07-06 |
2023-06-29 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Chimeric antigen receptor car or car construct targeting bcma and cd19 and application thereof
|
|
EP4192875A1
(en)
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
JP7821161B2
(ja)
*
|
2020-08-20 |
2026-02-26 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
CA3191224A1
(en)
|
2020-10-16 |
2022-04-21 |
Shenda GU |
Multispecific binding compounds that bind to pd-l1
|
|
WO2022094245A1
(en)
|
2020-10-30 |
2022-05-05 |
Vor Biopharma, Inc. |
Compositions and methods for bcma modification
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃａｒ－ｔ活性を調節するための方法及び組成物
|
|
CN113173991B
(zh)
*
|
2020-12-31 |
2023-03-28 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
MX2023008081A
(es)
|
2021-01-11 |
2023-09-12 |
Sana Biotechnology Inc |
Uso de vectores virales dirigidos a cd8.
|
|
JP2024507180A
(ja)
|
2021-02-16 |
2024-02-16 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
|
|
KR20230148828A
(ko)
|
2021-02-25 |
2023-10-25 |
테네오바이오, 인코포레이티드 |
항-psma 항체 및 car-t 구조
|
|
US20240182597A1
(en)
|
2021-02-26 |
2024-06-06 |
Teneobio, Inc. |
Anti-muc1-c antibodies and car-t structures
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
CN116997654A
(zh)
|
2021-03-17 |
2023-11-03 |
第一三共株式会社 |
编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
|
|
CN117321200A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
评估病毒载体颗粒效力的方法
|
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
KR20230166090A
(ko)
|
2021-04-06 |
2023-12-06 |
테네오바이오, 인코포레이티드 |
항-cd19 항체 및 car-t 구조체
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
JP2024517413A
(ja)
|
2021-04-16 |
2024-04-22 |
セルジーン コーポレーション |
以前に幹細胞移植を受けた患者におけるｔ細胞療法
|
|
CN117337303A
(zh)
|
2021-04-16 |
2024-01-02 |
特尼奥生物股份有限公司 |
抗cd20抗体及car-t结构
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
BR112023024231A2
(pt)
|
2021-05-19 |
2024-01-30 |
Sana Biotechnology Inc |
Células t primárias rhd negativas hipoimunogênicas
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
US20240316102A1
(en)
|
2021-07-01 |
2024-09-26 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
JP2024525727A
(ja)
|
2021-07-14 |
2024-07-12 |
２セブンティ バイオ インコーポレイテッド |
抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
|
|
KR20240046319A
(ko)
|
2021-07-14 |
2024-04-08 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
|
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
AU2022327174A1
(en)
|
2021-08-11 |
2024-02-15 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
MX2024004550A
(es)
|
2021-10-14 |
2024-04-29 |
Teneobio Inc |
Proteinas de union a la mesotelina y usos de las mismas.
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
MX2024005392A
(es)
|
2021-11-03 |
2024-08-06 |
Janssen Biotech Inc |
Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
|
|
KR20240112994A
(ko)
|
2021-11-03 |
2024-07-19 |
셀진 코포레이션 |
골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
CN119072319A
(zh)
|
2021-12-23 |
2024-12-03 |
萨那生物技术股份有限公司 |
用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
|
|
CN114276452A
(zh)
*
|
2021-12-29 |
2022-04-05 |
源道隆（苏州）医学科技有限公司 |
可结合bcma的纳米抗体及其应用
|
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
KR20250021397A
(ko)
|
2022-02-09 |
2025-02-12 |
하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 |
면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
CA3255500A1
(en)
|
2022-04-08 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
US20260035478A1
(en)
|
2022-07-27 |
2026-02-05 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
EP4311579A1
(en)
*
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B cell-specific mab-sirna conjugates improve myasthenia
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
EP4583876A1
(en)
|
2022-09-08 |
2025-07-16 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
AU2024226156A1
(en)
|
2023-02-21 |
2025-08-28 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
CN121152802A
(zh)
|
2023-04-18 |
2025-12-16 |
魁尔斯弗生物治疗股份有限公司 |
与ly6g6d结合的抗体
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
EP4716750A1
(en)
|
2023-05-23 |
2026-04-01 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
KR20260026101A
(ko)
|
2023-05-23 |
2026-02-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
US20250144234A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics Inc. |
RNA for In vivo Transfection with Increased Expression
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025109119A1
(en)
|
2023-11-22 |
2025-05-30 |
Priothera Sas |
Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
TW202602940A
(zh)
|
2024-04-09 |
2026-01-16 |
美商安進公司 |
激動性抗ｉｌ－２ｒｂｇ重鏈抗體
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
TW202544034A
(zh)
|
2024-05-06 |
2025-11-16 |
美商榮都醫療公司 |
結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|